TYMS and neoplasm: With adjustment for sex, age, tumor site and chemotherapy, rs3786362 in TYMS was observed to correlate with reduced PFS (HR = 1.37, 95% CI = 1.08-1.75, P = 1.10 × 10-2) and DCR (OR = 2.07, 95% CI = 1.24-3.44, P = 5.00 × 10-3) of mCRC patients in the additive model, which is consistent with the results mentioned above (Table 2 and Table 3).